Rising use of Fitbit wristbands, Withings scales and other self-tracking devices mean individuals have access to a pool of personal health data that in some respects far exceeds what clinical trials gather. Now, Validic has secured funding from Dallas Mavericks-owner Mark Cuban to bring the devices into healthcare.
Qlucore, a provider of scientific software, has won €600,000 ($801,360) over three years from the European Commission's 7th Framework Program to develop algorithms for use in personalizing treatment of hepatitis C virus.
Guilin Pharmaceuticals has advanced a system to combat use of fake antimalarial drugs. The Chinese drugmaker has launched an SMS-based system for patients in Africa to check whether their antimalarial meds are the real thing.
Novartis Oncology has unleashed a pair of mobile phone apps that cater to patients or doctors, building on the pharma giant's digital outreach efforts that already include multiple offers on app stores from Google and Apple.
Cancer patients might fail to follow their doctor's orders often. But how often do they forget their mobile phones?
Fresh data have emerged in the ongoing debate over the regulation of medical apps for smartphones and mobile devices. Researchers questioned the accuracy of four apps for evaluating skin lesions in a study, generating some troubling results and pointing out that such apps have gone unregulated.
Pfizer has decided to boost the profile of Lipitor in the digital realm, partnering with EatingWell magazine on a Lipitor-branded mobile app that includes 200 heart-healthy recipes that complement treatment with Pfizer's pill.
As we pack more data about our health into mobile devices, pharma companies could face a new competitive threat to their drugs: Mobile health apps.